Literature DB >> 870013

Treosulfan (dihydroxybusulphan) in the management of ovarian carcinoma.

J Fennelly.   

Abstract

Of 36 patients with ovarian carcinoma treated with treosulfan (dihydroxybusulphan) 30-5 per cent had a complete response for a mean of 19-0 months and 33-3 per cent had a partial response. Treosulfan may have a role in the management of ascites associated with ovarian neoplasm.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 870013     DOI： 10.1111/j.1471-0528.1977.tb12581.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN： 0306-5456


  4 in total

1.  The use of treosulfan and gemcitabine in the treatment of platinum-resistant ovarian cancer.

Authors:  S Hilman; P K Koh; S Collins; R Allerton
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

2.  Antitumor activity of treosulfan in human lung carcinomas.

Authors:  P Köpf-Maier; G Sass
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

3.  Antitumor activity of treosulfan against human breast carcinomas.

Authors:  P Köpf-Maier; G Sass
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool.

Authors:  M Y Eileen C van der Stoep; Dagmar Berghuis; Robbert G M Bredius; Emilie P Buddingh; Alexander B Mohseny; Frans J W Smiers; Henk-Jan Guchelaar; Arjan C Lankester; Juliette Zwaveling
Journal:  Sci Rep       Date:  2021-09-27       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.